8-[3-甲基-2-(3-吡啶基)-1H-吲哚-1-基]辛酸 | 87627-28-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 8-[3-甲基-2-(3-吡啶基)-1H-吲哚-1-基]辛酸
• 中文别名: 环戊酮,2,3-二羟基-2-甲氧基-3-甲基-,(3R)-
• 英文名称: 8-[3-methyl-2-(pyridin-3-yl)-1H-indol-1-yl]octanoic acid
• 英文别名: 1-(7-carboxyheptyl)-3-methyl-2-(pyridin-3-yl)-indole；3-methyl-2-(pyridin-3-yl)indole-1-octanoic acid；3-Methyl-2-(3-pyridinyl)-1H-indole-1-octanoic acid；3-methyl-2-(3-pyridyl)indole-1-octanoic acid；8-[3-methyl-2-(3-pyridyl)-1H-indol-1-yl]octanoic acid；1-(7-carboxy heptyl)-3-methyl-2-(3-pyridyl)indole；3-Methyl-2-(3-pyridyl)-1-indoleoctanoic acid；8-(3-methyl-2-pyridin-3-ylindol-1-yl)octanoic acid
• CAS: 87627-28-9
• 化学式: C₂₂H₂₆N₂O₂
• 分子量: 350.461
• InChiKey: CVVKIXNPXDBREE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  8-[3-甲基-2-(3-吡啶基)-1H-吲哚-1-基]辛酸 、 2-<<1-<<(benzyloxy)carbonyl>methyl>-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl>amino>-4-phenylbutanoic acid benzyl ester 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 8-(3-Methyl-2-pyridin-3-yl-indol-1-yl)-octanoic acid (3S,5R)-1-benzyloxycarbonylmethyl-3-((S)-1-benzyloxycarbonyl-3-phenyl-propylamino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl ester
  参考文献：
  名称：

  Dual Angiotensin Converting Enzyme/Thromboxane Synthase Inhibitors

  摘要：

  A variety of compounds were prepared to determine whether dual angiotensin converting enzyme (ACE)/thromboxane synthase (TxS) inhibition could be obtained in the same molecule. These compounds would be used to explore the concept that a dual inhibitor would have superior antihypertensive activity in the spontaneous hypertensive rat compared to an ACE inhibitor. Potent in vitro dual ACE and TxS inhibition was obtained in the same molecule with five series of compounds. Potent blood pressure lowering in the SHR was observed after oral administration of 8b and 11. However, a correlation between blood pressure lowering and the Al presser response inhibition was not observed. The blood pressure-lowering actions of enalapril were significantly potentiated by concurrent administration of 3, a thromboxane synthase inhibitor. Analysis of the area under the curve for 24 h showed nearly a doubling of the blood pressure-lowering effect.

  DOI：

  10.1021/jm00038a011
• 作为产物：
  描述：

  1-(7-methoxycarbonylheptyl)-3-methyl-2-(pyridin-3-yl)indole 生成 8-[3-甲基-2-(3-吡啶基)-1H-吲哚-1-基]辛酸
  参考文献：
  名称：

  RENFROE, H. B.

  摘要：

  DOI：

文献信息

• N-Substituted-2-pyridylindoles
  申请人：Ciba-Geigy Corporation

  公开号：US04478842A1

  公开（公告）日：1984-10-23

  Various 1-carboxylic acid substituted-2-pyridylindoles and functional derivatives thereof are highly specific thromboxane synthetase inhibitors. Synthesis of, pharmaceutical compositions thereof, and methods of treatment utilizing such compounds are included.

  各种1-羧基取代-2-吡啶基吲哚及其功能衍生物是高度特异的血栓素合成酶抑制剂。包括它们的合成、药物组合物以及利用这些化合物进行治疗的方法。
• Method for the improvement of cyclosporine therapy
  申请人：MERCK FROSST CANADA INC.

  公开号：EP0300675A2

  公开（公告）日：1989-01-25

  The present invention relates to a method for improving cyclosporine therapy, in particular a method for limiting cyclosporine induced nephrotoxicity which comprises the adjunct administration in a mammal of an effective amount of cyclosporine and an effective amount of an antithromboxane A₂ agent.

  本发明涉及一种改善环孢素治疗的方法，特别是一种限制环孢素诱导的肾毒性的方法，该方法包括在哺乳动物体内辅助施用有效量的环孢素和有效量的抗黄体生成素 A₂剂。
• A method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor and/or thromboxane receptor antagonist
  申请人：CIBA-GEIGY AG

  公开号：EP0449764A2

  公开（公告）日：1991-10-02

  A method of reducing serum uric acid and/or increasing renal clearance of uric acid in a mammal in need thereof comprising administering to such mammal a uricosuric effective amount of a thromboxane synthetase inhibitor, a thromboxane receptor antagonist, or both in a combined uricosuric effective amount is disclosed. Compositions having one or more of the foregoing in combination with one or more uricosurics are also set forth and included within this invention.

  本发明公开了一种降低有需要的哺乳动物的血清尿酸和/或增加其肾脏对尿酸的清除率的方法，该方法包括向哺乳动物施用尿酸有效量的血栓素合成酶抑制剂、血栓素受体拮抗剂或两者的组合尿酸有效量。具有一种或多种上述物质与一种或多种尿素合剂的组合物也被提出并包括在本发明中。
• Thromboxane inhibitors, compositions and methods of use
  申请人：——

  公开号：US20030050305A1

  公开（公告）日：2003-03-13

  The present invention describes methods for treating or preventing sexual dysfunctions in males and females, and for enhancing sexual responses in males and females by administering a therapeutically effective amount of at least one thromboxane inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The male or female may preferably be diabetic. The present invention also provides novel compositions comprising at least one thromboxane inhibitor, and, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and, optionally, at least one therapeutic agent, such as, vasoactive agents, nonsteroidal antiinflanmmatory compounds (NSAIDs), selective cyclooxygenase-2 (COX-2) inhibitors, anticoagulants, angiotensin converting enzymes (ACE) inhibitors, angiotensin II receptor antagonists, renin inhibitors, and mixtures thereof. The present invention also provides methods for treating or preventing ischemic heart disorders, myocardial infarction, angina pectoris, stroke, migraine, cerebral hemorrhage, cardiac fatalities, transient ischaemic attacks, complications following organ transplants, coronary artery bypasses, angioplasty, endarterectomy, atherosclerosis, pulmonary embolism, bronchial asthma, bronchitis, pneumonia, circulatory shock of various organs, nephritis, graft rejection, cancerous metastases, pregnancy-induced hypertension, preeclampsia, eclampsia, thrombotic and thromboembolic disorders, intrauterine growth, gastrointestinal disorders, renal diseases and disorders, disorders resulting from elevated uric acid levels and dysmenorrhea, and for inhibiting platelet aggregation or platelet adhesion or relaxing smooth muscles.

  本发明描述了治疗或预防男性和女性性功能障碍以及增强男性和女性性反应的方法，其方法是施用治疗有效量的至少一种血栓素抑制剂，以及可选的至少一种能捐献、转移或释放一氧化氮、提高内皮源性松弛因子的内源性水平、刺激一氧化氮的内源性合成或一氧化氮合酶底物的化合物和/或至少一种血管活性剂。男性或女性最好患有糖尿病。本发明还提供了新型组合物，其中包含至少一种血栓素抑制剂，以及至少一种能捐献、转移或释放一氧化氮、提高内皮源性松弛因子的内源性水平、刺激一氧化氮的内源性合成或作为一氧化氮合酶底物的化合物、以及至少一种治疗剂，如血管活性剂、非甾体抗炎化合物（NSAIDs）、选择性环氧化酶-2（COX-2）抑制剂、抗凝剂、血管紧张素转换酶（ACE）抑制剂、血管紧张素 II 受体拮抗剂、肾素抑制剂及其混合物。本发明还提供了治疗或预防缺血性心脏疾病、心肌梗塞、心绞痛、中风、偏头痛、脑出血、心脏病死亡、短暂性脑缺血发作、器官移植后并发症、冠状动脉搭桥术、血管成形术、动脉内膜切除术、动脉粥样硬化、肺栓塞、支气管哮喘、支气管炎、肺炎、各种器官的循环休克、肾衰竭、心肌梗塞、心绞痛、中风、偏头痛、脑出血、心肌梗塞、血管成形术、动脉内膜切除术、冠状动脉搭桥术、血管成形术、动脉内膜切除术、动脉粥样硬化、肺栓塞、支气管哮喘、支气管炎、肺炎的方法、各种器官的循环休克、肾炎、移植物排斥反应、癌症转移、妊娠高血压、子痫前期、子痫、血栓和血栓栓塞性疾病、宫内发育、胃肠功能紊乱、肾病和肾功能紊乱、尿酸水平升高引起的疾病和痛经，以及用于抑制血小板聚集或血小板粘附或松弛平滑肌。
• RENFROE, H. B.
  作者：RENFROE, H. B.

  DOI：——

  日期：——